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THE BIOPHYSICAL CHARACTERIZATION OF A NOVEL 
AMYLOIDOGENIC BETA2-MICROGLOBULIN VARIANT, P32L 
VICTORIA M. GIBSON 
ABSTRACT 
 Amyloidosis encompasses a group of diseases that are characterized by protein 
misfolding and irregular extracellular deposits formed by the buildup of non-native 
protein structures and amyloid fibrils in visceral organs and tissues.  There are over 35 
proteins having the potential to form amyloid deposits and fibrils in humans.  Amyloid 
pathologies are hereditary or can develop sporadically and exist in local and systemic 
forms.  In localized forms of the disease, amyloid deposits are limited to one tissue area 
or organ in the body, whereas the systemic types feature multiple sites of infiltration.  
There are many different systemic amyloid disease types, but this study focuses on a rare 
form of systemic amyloidosis known as beta2-microglobulin (ß2-m)-related amyloidosis. 
 The ß2-m protein, it is a 99-residue protein, that makes up the light chain portion 
of the class 1 major histocompatibility complex (MHCI) which is present of the surface 
of all nucleated cells.  ß2-m is usually cleared through the kidneys upon dissociation from 
MHCI.  However, patients with end stage renal failure can develop hemodialysis-related 
systemic amyloidosis when dialysis fails to remove ß2-m from the circulation and 
elevating concentrations of the protein lead to formation of amyloid fibrils.  
Alternatively, a hereditary form of ß2-m amyloidosis was identified in 2012 and reported 
to be associated with the gene mutation encoding the ß2-m variant, D76N. The 
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phenotypic expression in this type of ß2-m amyloidosis was very different from the 
dialysis-related disease associated with the wild-type protein. 
The present study focuses on a newly identified and unique amyloid-forming ß2-
m variant protein associated with a clinical presentation unlike the dialysis-related or 
previously reported hereditary form of ß2-m amyloidosis.  
 In 2019, a novel ß2-m variant was discovered at the Amyloidosis Center at Boston 
Medical Center.  A 59-year-old woman of Portuguese descent with a family history of 
cardiac amyloidosis presented with amyloid deposits in her fat tissue along with 
indications of cardiac involvement; the combination of these features led to a diagnosis of 
systemic amyloidosis.  DNA sequencing and mass spectroscopy revealed that the patient 
had a mutation in her ß2-m gene resulting in the replacement of leucine for proline at the 
32nd residue (P32L) of the ß2-m protein.  
 The aim of this research project was to understand the amyloid-forming nature of 
the P32L variant. To address this goal, we characterized the biophysical properties of 
P32L ß2-m.  The structural stability of P32L was compared to results for wild-type ß2-m, 
the previously described D76N amyloidogenic protein, and a synthetic variant with an 
alternative amino acid replacement at residue 32, P32G.  This latter protein was chosen as 
it has been previously studied and shown to have amyloidogenic properties in vitro.  
  Using a pQE-1 plasmid optimized for expression in E. coli, N-terminal MKH6 
tagged wild-type ß2-m, was produced and subsequently modified, to individually produce 
P32L, D76N, and P32G.  Variant plasmids were transformed in Rosetta-gami 2 cells for 
expression and purification.  Circular dichroism, chemical denaturation, and limited 
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proteolysis were used to assess protein secondary structure and stability.  Aggregation of 
variants was evaluated using Thioflavin T fluorescence and ultrastructural imaging of 
aggregates was accomplished with electron microscopy. 
 Results displayed that wild-type and variant ß2-m proteins showed similar 
secondary structures, all mainly comprised of beta-sheets.  Based on high percentages of 
beta-sheets and low amounts of unordered secondary structure, wild-type ß2-m was the 
most stable of the proteins and D76N was the least.  Moreover, wild-type had the highest 
apparent melting temperature followed by P32L, P32G and D76N.  In thermal unfolding 
and refolding experiments, wild-type exhibited an irreversible mechanism, while P32L 
was semi-reversible upon heating and cooling.  Chemical denaturation showed that D76N 
required the lowest concentration of guanidine hydrochloride to denature and wild-type 
the highest amount.  Aggregation of digestion products was apparent in both trypsin and 
thrombin reactions; electron microscopy demonstrated that trypsin treatment of P32L 
yielded pre-fibril oligomeric structures.  
 Overall, our data suggest that P32L and all variants were less stable than the wild-
type protein.  D76N appeared to be the least stable of the variants; P32L and P32G 
exhibited similar characteristics, both more stable than D76N and less stable than wild-
type.  The amyloid-forming nature of P32L ß2-m may be a result of the peptidyl-prolyl 
bond at P32 presenting in a trans conformation.  When P32 is in the thermodynamically 
favorable trans conformation, it has been shown to trigger amyloid formation.  This case 
was heterozygous for the mutation and the mixture of variant and wild-type proteins may 
destabilize the P32 isomer. 
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Protein Folding and Disease 
 Proteins, made up of amino acid polypeptide chains, are essential to the structure 
and function of cells.  They transport and store molecules, function as catalysts, provide 
immune protection and transmit nerve impulses1.  For these and many other actions to 
occur, it is vital that proteins be properly folded.  Incorrect folding can cause proteins to 
lose their function, and consequently, cell injury and disease can result2.  To function 
properly, the linear sequence of amino acids, synthesized on ribosomes, in eukaryotic 
cells, must fold into the proper native three-dimensional conformation within the 
endoplasmic reticulum or Golgi.  This is achieved through a funnel-like free energy state 
pathway, involving the formation of many intermediate conformations until the protein 






Figure 1.  Schematic of proteins folding to native state.  Unfolded proteins adopt many 
intermediate folded conformations before landing in their native conformation that is the 
most thermodynamically stable3.  
 
Proteins feature four levels of structure (Figure 2).  The primary structure is the 
linear sequence of amino acids which is synthesized based on genetic information from 
DNA, where each gene encodes for a unique sequence.  Once the amino acid sequence is 
synthesized on the ribosome, its secondary and tertiary structures begin to form in the 
cytoplasm or the endoplasmic reticulum4.  Alpha helices and beta sheets are folding 
patterns that constitute the secondary structure; they become prevalent as the protein is 
folded on a pathway to the native state.  Structural organization of the tertiary structure is 
stabilized by hydrogen bonds, disulfide bonds and hydrophobic interactions dictated by 
the amino acid sequence of the protein4.  When two or more polypeptide chains interact 
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with each other it creates the proteins quaternary structure, however proteins that are 
made up of one amino acid chain do not have quaternary structure3.  
 
 
Figure 2.  The four levels of protein structure.  The primary structure of proteins is 
made up of amino acids which form the secondary structure comprised of alpha helices 
and beta sheets.  The secondary structures are stabilized by side chain reactions that 
create the three-dimensional conformation which makes up the tertiary structure.  The 
quaternary structure is made up of two or more amino acid chains1. 
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During folding, hydrophobic residues will navigate to the core of the structure 
shielded from aqueous environments by hydrophilic residues on the outside of the 
protein.  Most of the time, proteins will achieve their native conformation with the help 
of chaperones and other proteins that assist in protein folding.  Chaperones, found within 
the endoplasmic reticulum (ER) in eukaryotic cells, assist newly translated proteins in 
transitioning to native conformations, as well as facilitate the refolding of misfolded 
intermediate species.  In addition, proteasomes and ER-associated degradation are 
cellular mechanisms in place to degrade proteins that are misfolded or unable to regain 
native conformational states.  Dysfunction within any one of these pathways can cause 
misfolded proteins to prevail and disease to occur. 
  Misfolding of proteins has been implicated in hundreds of diseases including, but 
not limited to, sickle cell anemia, cystic fibrosis, Alzheimer’s disease, Parkinson’s 
disease and systemic amyloidosis5.  Protein structural defects can occur spontaneously or 
misfolding can be the downstream result of a genetic mutation6.  Diseases featuring 
genetic coding abnormalities may be a consequence of variant proteins that exhibit either 
a loss or gain of function related to sequence alterations; in some cases, these structural 
changes can be toxic or even lethal7.  Misfolded or partially folded proteins allow for 
hydrophobic amino acids, usually buried in the interior of the molecule in a water-free 
environment, to be exposed and unprotected on the surface.  Exposed hydrophobic amino 
acids mediate protein self-association by interactions with similar residues to exclude 




In 1854, the term “amyloid” was first used by, the father of pathology, Rudolf 
Virchow, after identifying amorphous changes in tissues using an iodine staining reaction 
which indicated starch-like deposits9.  Today, amyloidosis encompasses a sizable group 
of diseases characterized by protein misfolding and irregular extracellular deposits 
formed by the buildup of the non-native structures and fragments10.  The accumulation of 
protein deposits composed of insoluble protein aggregates and fibrils occurs in tissues 
and visceral organs, most frequently the heart and kidneys11.  Amyloid deposits are 
composted of protein fibrils formed from parallel or anti parallel beta-pleated sheets 
comprised of polypeptides arranged in a zigzag formation (Figure 3)12,13.  
 
 
Figure 3.  Amyloid fibril assembly cascade.  Unfolded or misfolded proteins can form 




 It is this organized ultrastructural arrangement that allows identification of 
amyloid deposits with the dye, Congo red, as illustrated in Figure 4A showing results on 
a fat pad biopsy14.  All amyloid deposits demonstrate apple-green birefringence under a 
polarized view by light microscopy when stained with Congo red (Figure 4B)14.  The 
ultrastructure of amyloid deposits features non-branching fibrils, typically 7.5 to 10 nm in 
diameter, which can be identified using electron microscopy (Figure 4C)11,15.   
 
 
Figure 4.  Microscopic imaging of amyloid deposits and fibrils.  Congo red staining of 
amyloid deposits in a fat pad biopsy (A).  Amyloid deposits show apple-green 
birefringence when viewed by light microscopy under a polarized view (B).  Electron 
microscopy can be used to visualize non-branching fibrils in amyloid deposits (C)9,11,15.  
 
There are over 35 known proteins identified as having the potential to form 
amyloid fibrils and deposits in humans (Table 1)14.  Acquisition of amyloidosis can be 
either sporadic or hereditary16.  Amyloid pathologies are associated with the specific 
amyloid-forming protein, but can be generally described in two categories, localized or 
systemic, based on the location of amyloid deposits in the body.  In localized forms of the 
disease, amyloid deposits are limited to one tissue area or organ in the body; conversely, 
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systemic amyloid diseases feature deposits in multiple organs and tissues throughout the 
body.  Examples of localized amyloidosis include: 1) ß-protein infiltration and deposition 
in the brain found in Alzheimer’s disease, and 2) islet amyloid polypeptide, also known 
as amylin, accumulation of amyloid deposits in the pancreas and associated with diabetes 
mellitus type 29.  There are many different types of systemic amyloidosis including the 
three most common, immunoglobulin light chain (AL) amyloidosis, amyloid A (AA) 






















AL amyloidosis, also known as primary amyloidosis, is the most common and 
rapidly progressing type of systemic amyloidosis14.  In AL amyloidosis, fibrils are made 
up of monoclonal immunoglobulin light chains, while this is usually a systemic acquired 
disease, it can also occur as a localized form17.  Individuals with AL amyloidosis 
typically have a monoclonal gammopathy, a disorder where clonal plasma cells in the 
bone marrow proliferate causing an increase in immunoglobulin light chain production.  
Amyloid fibrils formed from aggregated light chain proteins and fragments progressively 
target multiple tissues and organs where deposits cause organ dysfunction, damage, and 
death if untreated17.  
Secondary amyloidosis or AA amyloidosis is another form of non-hereditary 
systemic amyloidosis that is caused by prolonged elevated concentrations of serum 
amyloid A (SAA) protein, an acute phase reactant.  Serum levels of SAA can increase 
1000-fold during an inflammatory response and in chronic disorders like rheumatoid 
arthritis and hereditary autoinflammatory diseases, AA amyloidosis may occur as a 
secondary morbidity17,18.  With medical advances providing effective control of many 
chronic inflammatory disorders over the last several decades, a substantial decline in 
cases of AA amyloidosis throughout the world has been observed19.  
ATTR amyloidosis is most often a systemic disease that can develop sporadically 
or through inheritance20.  Sporadically occurring, non-genetic disease is caused by 
misfolding and aggregation of wild-type transthyretin (TTRwt), normally a circulating 
plasma protein; this is an age-related disorder mainly featuring cardiac amyloid deposits 
known as wild-type TTR amyloidosis (ATTRwt) or senile systemic amyloidosis (SSA).  
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While sporadically occurring ATTR amyloidosis is a consequence of misfolded TTRwt, 
inherited forms of the disease occur as a result of inherited TTR gene mutations.  There 
are over 100 TTR point mutations, each encoding a destabilized protein variant that 
misfolds and forms amyloid fibrillar deposits21; ATTR amyloidosis associated with TTR 
mutants (ATTRm amyloidosis) is the most frequent hereditary form of amyloidosis22.  
Previously referred to by clinical phenotype, i.e. familial amyloid cardiomyopathy (FAC) 
or familial polyneuropathy (FAP), ATTRm amyloidosis commonly presents as 
cardiomyopathy and/or peripheral neuropathy22. 
Another systemic form of amyloid disease is ß2-microglobulin (ß2-m) 
amyloidosis.  This pathology is typically seen in patients with end stage renal failure who 
are undergoing hemodialysis treatment.  However, analogous to ATTR, both sporadic 
and hereditary cases of systemic ß2-m amyloidosis have been described23.  The latter 
circumstance featuring inherited disease attributed to a ß2-m mutation is the subject of 
this thesis research. 
 
Beta2-microglobulin Related Amyloidosis 
 Beta2-microglobulin (ß2-m) is a 99 amino acid residue protein, with a molecular 
weight of approximately 11.8 kDa, that makes up the light chain portion of the class I 
major histocompatibility complex (MHCI)23.  The MHCI, present on the surface of 
almost all nucleated cells, is assembled in the endoplasmic reticulum before being 
transported to the cell membrane and positioned on the extracellular side, anchored by a 
transmembrane domain23.  ß2-m lies directly below MCHI molecule 1 and is attached at 
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the D-E loop of the ß2-m protein, but does not have a transmembrane component (Figure 
5A, 5B)24.   
Typically, very stable under physiological conditions, ß2-m has an anti-parallel ß-
strand structure that conforms into a ß-sandwich motif representative of the 
immunoglobulin superfamily.  A ribbon diagram of the protein showing the 7 ß-strands 
designated A-G is shown in Figure 5B25.  ß2-m is further stabilized by the single 
disulfide bond between the ß-strands B and F at Cys 25 and Cys 80 (Figure 5B)24.  There 
are five peptidyl-prolyl bonds including one at P32 that can be in a trans or cis 
conformation; when P32 is in the trans conformation, it has been shown to trigger 











Figure 5.  Beta2-microglobulin protein.  The D-E loop of the ß2-m protein is attached 
to the 1 molecule of the major histocompatibility complex class I (A).  Ribbon diagram 
representation of the ß2-m protein comprised of 99 amino acid residues, seven ß-sheet 
strands labelled A-G (shown in purple) from C- to N-terminus in direction, and one alpha 
helix (shown in green) (B).  The white arrow denotes the cystine bond between the B and 
F strands24,25. 
 
Upon MHCI catabolism, ß2-m dissociates from the MHCI and is cleared through 
the kidneys, predominantly in the proximal tubules24.  Patients with end stage renal 
failure can experience an increase of ß2-m in their bloodstream, which is a consequence 
of dialysis, specifically with the membrane cuprophane, not removing ß2-m proteins 
(Figure 6)15,27.  Plasma concentrations of the ß2-m protein, normally 1 to 2 mg/L, can rise 
50 to 70 times that amount when patients are undergoing dialysis treatment.  Increased 
concentrations of ß2-m have been shown to lead to amyloid fibrils formation in vitro20,28.  
In affected patients, the higher levels of circulating ß2-m causes amyloid deposits to 
accumulate in osteoarticular tissues resulting in bone destruction and dialysis-related 
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amyloidosis24.  Findings have not shown a strong correlation between ß2-m concentration 
and fibril load, indicating that other factors likely contribute to protein aggregation 
including patients age, duration of dialysis and post translational modification of ß2-m24.  
 
 
Figure 6.  Progression of dialysis related amyloidosis.  Schema showing the disease 
pathway steps leading from ß2-m as a component of the surface-bound MHCI of a 
nucleated cell to ß2-m fibril deposition in joints15.  
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Alternatively, a novel hereditary systemic form of ß2-m amyloidosis was first 
described almost 10 years ago in several members of a French family.  In 2012, the 
kinship was reported to have an amyloidogenic ß2-m mutation encoding the replacement 
of aspartic acid with asparagine at residue 76 (D76N) in the ß2-m protein15.  This was the 
first known amyloid-forming ß2-m variant protein (Figure 7)15,23.  ß2-m hereditary 
amyloidosis is caused by a genetic abnormality and resultant variant rather than the 
accumulation of wild-type ß2-m protein as seen in dialysis-related amyloidosis.  ß2-m 
amyloidosis associated with the D76N variant was described with a very different 
presentation than the dialysis-related disease, in that many organs and tissues throughout 
the body were affected, not just the joint tissues23.  Moreover, the D76N phenotype 
featured normal plasma ß2-m concentration and preserved renal function.  MHCI was 
shown to act as a chaperone which stabilized the D76N ß2-m variant on the surface of 
cells; however, it appeared that the protein became unstable and fibrillogenic after 
dissociation from MHCI.  Halabelian et al. demonstrated that the substitution of 
asparagine for aspartic acid at residue 76 in the ß2-m polypeptide chain dramatically 
decreased the stability and increased the aggregation propensity of the protein23.  
Furthermore, this variant form of ß2-m has been shown to evade proteosomes and other 






Figure 7.  The secondary structure of D76N variant ß2-m protein.  Ribbon diagram 
representation of ß2-m with replacement of aspartic acid by asparagine at reside 76 in the 
E-F loop of the protein, shown in the box portion of the figure15.   
 
Hereditary P32L ß2-m Amyloidosis - Clinical Background and Diagnosis 
 In 2019, a novel ß2-m variant was discovered at the Amyloidosis Center at Boston 
Medical Center (BMC).  A patient arrived at BMC complaining of dyspnea that had 
progressed over the past several years, especially when met with physical demands such 
as climbing stairs.  She was a 59-year-old Caucasian woman of Portuguese descent 
having relocated to the United States at a young age.  Her family had a history of heart 
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disease and coronary artery disease (CAD).  She was predeceased by her son and 
daughter who both died before the age of one due to spinal muscular atrophy type 1 also 
known as Werdnig-Hoffmann Disease (Figure 8).  A medical history of the patient 
included tuberculous (TB) as a child, chronic obstructive lung disease (COPD), CAD, 
paroxysmal atrial fibrillation (PAF), chronic interstitial lung disease (ILD).  She was a 
smoker for six years but had since stopped; she denied consumption of alcohol.  Another 
contributing factor included previous exposure to pesticides.  On arrival to BMC, the 
patient presented with restrictive cardiomyopathy, low voltage EKG, high blood pressure, 
and hyperlipidemia.  
 
 
Figure 8.  Family pedigree of BMC case heterozygous for the P32L ß2-m mutation.  
The black arrowhead and red insert denote the proband with the Pro32Leu ß2-m mutation 
associated with amyloidosis.  Circles indicates females and squares indicate males.  
Clinical features and age at time of death for deceased family members (represented by a 
slash) are indicated where information was available.  
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At the initial visit, extensive amyloid deposition in a fat pad aspirate was revealed 
by Congo red staining (Figure 9).  The occurrence of amyloid in the fat tissue along with 
other indications of cardiac involvement provided a tissue diagnosis of systemic 
amyloidosis.  However, the type of amyloid disease was unclear as markers for AL 
amyloidosis and genetic testing for hereditary TTR amyloidosis, the most common types 
of amyloidosis were negative.  Mass spectrometry analysis of a Congo red positive 
endomyocardial biopsy identified the protein in the cardiac amyloid deposits as ß2-m and 
thus, a determination of Aß2-m amyloidosis was made.   
 
 
Figure 9.  Amyloid deposition in fat pad aspirate from patient.  Congo red-positive 
amyloid deposits viewed by light microscopy in fat tissue (A).  Polarized light view 
demonstrating apple-green birefringence of Congo red-positive amyloid deposits in fat 
pad aspirate (B).   
 
DNA sequencing of the three ß2-m gene coding regions showed an abnormality in 
exon 2.  Two nucleotide transitions at positions 154 and 155 were observed, with thymine 
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(T) replacing cytosine (C) in both cases.  Together, the nucleotide transitions at the first 
and second base positions in codon 52 (codon 32 of the mature protein) encoded the 
replacement of proline with leucine (CCA/TTA or CCA/CTA) or serine (CCA/TCA) at 
residue 32 in the ß2-m protein (Figure 10).   
 
 
Figure 10.  Partial sequence chromatogram from Sanger DNA sequencing of ß2-m 
gene exon 2 from the proband.  The two vertical black arrows denote the observed 
dinucleotide transitions, c.154C>T and c.155C>T, that were identified in the proband (II-




The gene sequencing analysis did not allow determination as to whether the two 
nucleotide alterations were on the same or separate alleles; thus, the exact identity of the 
amyloid forming ß2-m variant, P32L or P32S, required further protein characterization. 
Mass spectrometry (MS) was used to identify the ß2-m protein species in circulation and 
in the amyloid deposits.  Analyses of plasma sample showed the presence of both wild-
type and P32L ß2-m proteins (Figure 11).  
 
 
Figure 11.  Mass spectrometry analysis of plasma sample from patient.  Mass 
spectrum of plasma sample from the proband (II-3) showing both wild-type and P32L 
variant (A).  Mass spectrum of a control plasma sample containing only wild-type ß2-m 
(B).   
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Liquid chromatography tandem mass spectrometry analysis of Congo red positive 
tissue from an endomyocardial biopsy demonstrated that the P32L variant was present in 
the amyloid deposits and thus, verified the ß2-m mutation in the proband.  Further 
analysis by MS based proteomics of the congophilic amyloid deposits in the 
endomyocardial biopsy identified 52.9% coverage of the ß2-m amino acid sequence 
(Figure 12).  In addition, only the variant protein, P32L ß2-m, was detected in the cardiac 










Figure 12.  MS/MS spectrum and amino acid sequence coverage of ß2-m protein 
found in endomyocardial tissue from the proband.  Liquid chromatography tandem 
mass spectrometry results showing the variant peptide.  The red asterisk indicates the 
P32L variant found in the proband sample (A).  The amino acid sequence of ß2-m is 
shown with bolded letters indicating those residues identified by mass spectrometry-
based proteomics and contributing to 52.9% sequence coverage in the analysis of ß2-m 
peptides.  The replacement of proline (P) with leucine (L) is indicated by red font; there 





Goals of Research 
In this thesis project, we studied a newly identified ß2-m variant with an amino 
acid substitution at residue 32, where proline is replaced with leucine.  Several unique 
and interesting aspects of the P32L ß2-m protein prompted our investigations.  This is 
only the second reported ß2-m amyloidogenic variant protein.  The clinical presentation 
in this amyloid case was unlike those previously described in the dialysis-related or 
D76N hereditary forms of ß2-m amyloidosis.  Moreover, whereas the vast majority of 
hereditary amyloid cases feature amyloid variant proteins that arise from point mutations 
in the genes that encode those proteins, this ß2-m amyloidosis featured a double mutation 
and was not located in the same region as the previously reported amyloidogenic 
abnormality, D76N.   
The goal of our study was to better understand what causes ß2-m P32L to form 
amyloid fibrils by defining the biophysical properties of the protein.  Using 
recombinantly generated proteins, we characterized the structure and stability of P32L 
and compared these data to results obtained on the wild-type, and amyloidogenic variant, 
D76N.  In addition, the synthetic variant, P32G, with an alternate replacement at residue 
32, was assessed as this protein has been previously shown to exhibit amyloidogenic 








Chemicals and Reagents 
Plasmid with human wild-type beta2-microglobulin (ß2-m) encoding sequence 
was purchased from GenScript Biotech (Piscataway, NJ).  Primers were purchased from 
Invitrogen (Carlsbad, CA).  All other materials were purchased from Thermo Scientific 
(Waltham, MA), Sigma (St. Louis, MO) or Invitrogen (Carlsbad, CA), and were of the 
highest grade available.  
Site Directed Mutagenesis  
The pQE-1 plasmid with a DNA sequence optimized for expression in E. coli of 
N-terminal Met-Lys-His6 (MKH6)-tagged human wild-type ß2-m was used for site 
directed mutagenesis.  The QuickChange II Site-Directed Mutagenesis Kit 
(Invitrogen/Thermo Fisher Scientific, Waltham, MA) was used to produce three separate 
pQE-1 plasmids, each encoding one of the following N-terminal (MKH6)-tagged ß2-m 
variants: D76N, P32L and P32G.  The sequences for the mutant ß2-m primer sets are 
shown in Table 2 with the mutation region for each underlined.  Polymerase chain 









Table 2.  ß2-m primer sets for each mutant  
D76N sense 5’-CCCCGACCGAAAAAAACGAGTATGCGTGCCG-3’ 
D76N anti 5’-CGGCACGCATACTCGTTTTTTTCGGTCGGGG-3’ 
P32L sense 5’-GCTATGTGAGCGGTTTCCACCTGAGCGACATCGAAGTGG-3’ 
P32L anti 5’-CCACTTCGATGTCGCTCAGGTGGAAACCGCTCACATAGC-3’ 
P32G sense 5’-GAGCGGTTTCCACGGGAGCGACATCGAAGTGG-3’ 
P32G anti 5’-CCACTTCGATGTCGCTCCCGTGGAAACCGCTC-3’ 
 
PCR products for each mutant sequence were generated using individual primer 
sets with the materials and protocol detailed in Tables 3 and 4. 
 
Table 3.  Reagents used in polymerase chain reaction 
Material Amount 
DNA (MK(6H)Qß2mP32G/pQE-1), 10 ng 0.5 µL 
10X reaction buffer 2.5 µL 
P32Gfor, 125 ng 7.3 µL 
P32Grev, 125 ng 5.3 µL 
dNTP, 10 mM 0.5 µL 
diH20 8.9 µL 
Pfu Ultra HF DNA polymerase  0.5 µL 






Table 4.  Protocol used in amplification procedure  
PCR Conditions 
Step T (C) Time 
1 95 C 30 sec 
2 95 C 30 sec 
3 55 C 1 min 
4 68 C 6 min 
5 Steps 2-4 21 times 
6 68 C 30 sec 
7 4 C Until digested 
 
The PCR products were digested with 0.5 µL of DpnI enzyme, incubated for 1 hr 
at 37 C, and stored at -20 C.   
Transformation of E. coli into XL1-ultracompetent cells  
The ß2-m variant plasmids (MK(6H)Qß2m/pQE-1) were transformed into XL1-
ultracompetent cells.  XL1- ultracompetent cells (25 µL) were thawed on ice before 2 µL 
of the DpnI treated PCR products were added.  Samples were incubated on ice for 30 
min, heat shocked for 45 sec at 42 C, and then incubated on ice for 2 more min.  
Preheated NZY+ broth was added to the mixture and incubated for 1 hr at 37 C with 
shaking at 225 rpm.  Following the incubation period, 140 µL of the solution was plated 
onto LB plates containing 100 µg/mL ampicillin (amp) and allowed to stand at 37 C for 
a minimum of 16 hr.  Single bacterial colonies were isolated for DNA extraction.  
DNA Extraction  
Plasmid DNA was isolated from cell cultures using PureLink Quick Plasmid 
Miniprep Kits (Invitrogen/Thermo Fisher Scientific, Waltham, MA).  A single colony 
from each plate was placed into a cell culture tube with 5 mL of LB/amp (100 µg/mL) 
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broth.  The tubes were incubated overnight at 37 C while shaking at 225 rpm.  Tubes 
were spun at 4,900 rpm and 4 C for 10 min; supernatant was subsequently discarded.  
Cell pellets were resuspended in 250 µL of resuspension buffer with RNase A.  Lysis 
buffer (250 L) was added and mixed by inverting the tube until the solution appeared 
homogeneous.  The solution was incubated at room temperature for 5 min.  Next, 350 µL 
of precipitation buffer was added and mixed by inverting the tube.  Lysate was 
centrifuged at 12,000 x g for 10 min.  Supernatant was loaded onto a spin column in a 2 
mL wash tube and centrifuged at 12,000 x g for 1 min.  The flow-through was discarded, 
the column placed back in the wash tube, and 500 L of wash buffer with 70 % ethanol 
was added to the column.  After standing for 1 min at room temperature, the column was 
centrifuged at 12,000 x g for 1 min, the flow-through discarded, and the column was 
placed back in the wash tube.  Next, 700 µL wash buffer with 70 % ethanol was added to 
the column and centrifuged at 12,000 x g for 1 min.  Flow-through was discarded and the 
column was centrifuged at 12,000 x g for 1 min with the flow-through again discarded.  
The spin column was subsequently placed into a clean 1.5 mL elution tube and plasmid 
DNA was eluted with 50 µL diH2O.  The column was centrifuged at 12,000 x g for 2 min 
and the flow-through containing the purified plasmid DNA was collected.  DNA 
concentration was determined using nanodrop (Thermo Fisher Scientific, Waltham, MA) 
by measuring absorbance at 260 nm.  The accuracy of ß2-m mutant plasmid sequences 





Polyacrylamide Gel Electrophoresis (PAGE) 
 Most gels were pre-cast using materials listed in Tables 5 and 6.  For a 15% 
acrylamide-based resolving gel, reagents were combined and poured into a Bio-Rad 
(Hercules, CA) gel casting apparatus containing glass plates separated by 1.5 mm spacers 
until two-thirds full.  Isopropyl alcohol was carefully layered on top of the resolving gel 
solution to create a uniformed edge.  Once the 15% resolving gel solution solidified, the 
isopropyl alcohol was poured off and the cast was dried.  Materials to make the 5% 
stacking gel solution were mixed and poured on top of the resolving gel.  A 10 to 15 well 
comb was placed into the stacking gel solution and was carefully removed once the 
stacking gel had solidified.  
 
Table 5.  15% PAGE resolving gel reagents 
Materials Volume 
H20 7.1 mL 
40% Acrylamide 7.5 mL 
1.5 M Tris pH 8.8 5.0 mL 
10% SDS 0.2 mL 
10% APS 0.2 mL 
TEMED 8 µL 
 
Table 6.  5% PAGE stacking gel reagents  
Materials Volume 
H20 7.3 mL 
40% Acrylamide 1.25 mL 
0.5 Tris pH 6.8 1.25 mL 
10% SDS 0.1 mL 
10 % APS 0.1 mL 




SDS loading buffer (2X) with reducing agent BME (5 %) was added to each 
reaction aliquot in a 1:1 volume to volume (v/v) ratio.  Samples were heated at 98 C for 
10 min, loaded on a 15 % SDS-PAGE pre-cast tris-glycine gel, and electrophoresed for 1 
hr at 150 V.  Gels were stained with Coomassie blue and de-stained in diH20, methanol 
and acetic acid in a ratio of 50/40/10 (v/v/v); each step was carried out for 1 hr with 
shaking.  
Expression and purification of beta2-microglobulin proteins 
The ß2-m variant plasmids (MK(6H)Qß2m/pQE-1) were transformed into Rosetta-
gami 2(DE3) competent cells.  Rosetta-gami 2(DE3) cells (100 µL) were thawed on ice 
before 10 µL of plasmid DNA was added.  Samples containing plasmid and cells were 
incubated on ice for 30 min, heat shocked for 45 sec at 42 C, and then incubated on ice 
for 2 additional min.  Preheated SOC media was added to the mixture and the samples 
were incubated for 1 hr at 37 C while shaking at 225 rpm.  Following the incubation 
period, 140 µL of the solution was applied to LB plates containing ampicillin (100 
g/mL) and incubated at 37 C for a minimum of 16 hr.  Overnight cultures grown in 
LB/amp (100 µg/mL) media were initiated from single bacterial colonies.  The next day, 
overnight cultures were put into a 32.5 % glycerol, 0.5 M MgSO4, 13.5 mM Tris pH 8 
solution and were flash frozen using acetone and dry ice. Samples were stored at -80 C 
for future use.  
The transformed E. coli Rosetta-gami 2 cells containing DNA sequences coding 
for N-terminal 6-His tagged variants (D76N, P32L, or P32G) or wild-type were 
separately prepared for expression.  For each protein, three test tubes, with 6 mL of LB 
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broth supplemented with ampicillin (100 µg/mL) per 1 L cell culture, were inoculated 
with a loop full of previously frozen ß2-m cell culture.  Test tubes were incubated 
overnight at 37 C while shaking at 225 rpm.  Four flasks of LB/amp broth were 
autoclaved and equilibrated to 37 C.  The following day, the 1 L flasks of LB/amp 
media were inoculated with 3 x 6 mL tubes of overnight culture.  The 1 L cultures were 
incubated at 37 C with shaking at 225 rpm for 3 to 4 hr until the OD600 of the culture 
solution was between 0.6 – 0.8.  Cultures were moved to a chamber in the cold room and 
equilibrated to 12 C while shaking at 225 rpm.  Expression of recombinant ß2-m protein 
was induced by adding isopropyl -D-1-thiogalacto-pyranoside (IPTG) at a final 
concentration of 0.12 mM, to each flask.  Cultures were incubated at 12 C for 19-20 hr 
while shaking at 225 rpm.  Following incubation, media was centrifuged in an SLA-1500 
rotor at 6,000 rpm and 4 C for 20 min.  The supernatant was discarded, the cell pellets 
were resuspended in phosphate buffered saline (15 mM NaCl, 5 mM sodium phosphate at 
pH 7.4) and centrifuged in a swinging bucket at 3,900 x g and 4 C for 20 min.  The 
supernatant from this spin was discarded and pellets were stored overnight at -20 C.  
 Purification of proteins was accomplished through binding of the N-terminal 6-
His tagged-proteins to a Ni bound agarose.  Cell pellets were thawed on ice for 15 min 
and resuspended in immobilized metal ion affinity column (IMAC) cell lysis buffer 
containing 1 mg/mL of lysozyme, at a buffer/pellet ratio of 3 mL/gram wet weight; 
suspensions were placed on ice for 30 min.  Cells were sonicated while on ice over a 2 
min interval, in 15 sec increments for each pellet to control for overheating, and 
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centrifuged in a SS-34 rotor at 9,000 rpm and 4 C for 30 min.  Supernatants were filtered 
through a 0.22 m syringe-tip filter into a 50 mL conical tube. 
 An IMAC column with 2 mL of Ni-NTA agarose was equilibrated using 
approximately 40 mL of sample buffer (15 mM NaCl, 5 mM sodium phosphate, pH 7.4).  
Up to 20 mL of cell lysate was loaded onto the column and maintained at room 
temperature while rocking for 1 hr.  Flow-through was discarded and the column flushed 
with IMAC wash buffer until the OD280 nm was zero.  Subsequent to this wash step, 
IMAC elution buffer was run through the column and collected in 1 mL fractions.  
Fractions that had an OD280 nm > 0.5 were collected and pooled.  An Econo-Pac 10DG 
desalting column (Bio-Rad, Hercules, CA), used to exchange buffers, was equilibrated in 
sample buffer and loaded with 3 mL of IMAC-eluted sample having an approximate 
protein concentration of 2 mg/mL.  Protein was exchanged into 4 mL of sample buffer. 
Concentration of proteins was calculated from measurement of UV absorption at 280 nm 
using the extinction coefficient of 20,065 M-1cm-1.  Protein samples were aliquoted, flash 
frozen using acetone and dry ice, and stored at -80 C.  Biochemical analysis of the 
purified recombinant ß2-m proteins was performed by electrophoresis on tris glycine (8-
16%) gels, as previously described.  
Recombinant protein N-terminal His tag removal  
The N-terminal MKH6 tags present on all recombinantly generated ß2-m proteins 
were removed from purified samples using the enzyme, TAGZyme DAPase (Qiagen, 
Hilden, Germany).  Initially, an experiment was performed to determine conditions that 
would yield the most optimal results.  Solutions of diluted (1/10) DAPase enzyme stock 
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(10 U/mL) and cysteamine HCl (20 mM) were prepared using 1X TAGZyme buffer.  A 
2:1 (v/v) solution of cysteamine HCl (2 mM) to DAPase (1 U/mL) was made and allowed 
to stand for 5 min at room temperature.  Digestion was initiated by adding 15 µL (50 mU 
DAPase/mg protein) of the enzyme solution to 50 µg of recombinant ß2-m protein, the 
maximum suggested enzyme:substrate proportion.  The mixture was allowed to stand at 
room temperature or at 37 C for 1 hr and 48 hr. Samples (20 µL) were removed at timed 
intervals (0, 1, and 48 hr) for analysis by SDS-PAGE as previously described.   
 Based on initial testing, a 1:1 ratio of DAPase (10 U/mL) to cysteamine HCl (20 
mM) was prepared and allowed to stand at room temperature for 5 min.  Recombinant 
proteins were equilibrated to room temperature and 10 L (50 mU DAPase/mg protein) 
of the DAPase/cysteamine HCl solution was added to 1 mg/mL of protein.  The reaction 
solution was allowed to stand for 1 hr at room temperature; during this interval, 1 mL of 
50 % Ni-NTA agarose was equilibrated in a disposable column with 5 mL sample buffer 
in preparation for isolation of the untagged ß2-m proteins by IMAC and removal of 
excess enzyme and His tag components.  Once digestion was completed, the reaction 
mixture was applied to the column and flow-through collected.  Protein concentration 
was calculated from measurement of UV absorption at 280 nm using the extinction 
coefficient of 20,065 M-1cm-1.  Removal of the His tag was confirmed by SDS-PAGE 
analysis as previously described.  Proteins were flash frozen using acetone and dry ice, 





Circular Dichroism Spectroscopy  
Circular dichroism (CD) data were obtained from a Jasco J-815 
spectropolarimeter (Oklahoma City, OK) which was equipped with a thermoelectric 
temperature controller.  Separate samples of recombinant wild-type and variant (D76N, 
P32L, and P32G) ß2-m, with and without His tags, were solubilized in sample buffer to a 
concentration of 0.25 mg/mL (22 µM).  Individual solutions were placed in a 1 mm path 
length quartz cell and far UV CD spectra (195 – 250 nm, 1 nm bandwidth) were collected 
at both 25 C and 75 C.  Spectral data were smoothed using the Jasco noise reduction 
routine, normalized to protein concentration, and presented in molar residue ellipticity 
(MRE) values.  The secondary structures of ß2-m proteins (wild-type and variants) were 
estimated from far UV CD spectra using the CDSSTR method in the CDpro program 
(Jasco, Oklahoma City, OK).  
The thermostabilities of wild-type and variant ß2-m were assessed by CD melting 
experiments with monitoring at 205 nm.  Protein samples, each at a concentration of 0.25 
mg/mL (22 µM) in sample buffer, were placed into a 1 mm path length quartz cell and 
studied individually.  A fast melt over the temperature range 25 - 75 C at a rate of 1 
C/min was conducted followed by a reverse melt from 75 - 25 C performed under 
identical conditions.  Apparent melting temperatures (Tm app) for wild-type, D76N, P32L 
and P32G ß2-m were calculated by determining the values of the first derivatives from the 
CD melting curves.  Melting curves were smoothed and normalized using SigmaPlot 




Chemical Denaturation  
 Chemical denaturation was performed using guanidine hydrochloride.  A group of 
ß2-m samples (wild-type and variants), with and without a His tag, were prepared by 
solubilizing 0.02 mg/mL protein in sample buffer containing incrementally increasing 
concentrations of guanidine HCl, ranging from 0 M – 4.6 M.  Samples were allowed to 
stand at room temperature for 2 hr and assessed for fluorescence on a FluoroMax-4 
Spectrofluorometer (Horiba Jobin Yvon, Kyoto, Japan) by monitoring emission from 300 
– 450 nm following excitation at 280 nm.  Data were analyzed by calculating the 
fluorescence intensity ratio at 355 nm/335 nm and were normalized between 0 and 1 to 
reflect the fraction of protein that was unfolded.  
Limited Proteolysis  
Limited proteolysis of all ß2-m proteins, with and without His tags, was monitored 
in separate digestions with trypsin and thrombin.  Initially, an experiment was performed 
to determine conditions that would yield the most optimal results with trypsin.  Wild-type 
and variant P32L ß2-m proteins were solubilized in sample buffer to a concentration of 
0.35 mg/ml.  Solutions were either placed in a screw topped glass vial, an eppendorf tube, 
or split up into individual PCR tubes for each time point.  Before adding trypsin, 20 µL 
from each container was removed and served as the 0 time-point.  Proteolysis was 
initiated with the addition of trypsin to the protein solution, at an enzyme to substrate 
ratio of 1:100, in the glass vial, eppendorf tube and each of the PCR tubes, all at 37 C. A 
20 L aliquot was removed from the reaction mixture located in the glass vial or 
eppendorf tube, at each of the following time points:  5, 30, 60, and 120 min.  PMSF, at a 
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final concentration of 6 mM, was added to stop all reactions.  In addition, at each time 
point listed above, PMSF, at a final concentration of 6 mM, was added to all 
corresponding PCR tubes.  All reaction samples were frozen and stored at -4 C for 
analysis by SDS-PAGE as described in preceding paragraphs.  
Based on initial testing, a screw top glass vial was used in the following 
proteolysis experiments with trypsin and thrombin.  For experiments with trypsin, each 
protein (wild-type or variant) was solubilized in sample buffer to a concentration of 0.35 
mg/mL.  Solutions were individually placed in screw topped glass vials.  Before starting 
the experiment, 20 µL was removed from the test solution and served as the 0 time point 
sample.  Proteolysis was initiated with the addition of 35 L of 0.05 mg/ml trypsin to the 
protein solution at an enzyme to substrate ratio of 1:100.  Solutions were kept at 37 C 
for the duration of the experiment.  A 20 L aliquot was removed from the reaction 
mixture at each of the following time points:  5, 10, 30, 60, 90, 120, 240, and 360 min; 
PMSF, at a final concentration of 6 mM, was added to stop the digestion reaction.  
An identical protocol was used to study proteolysis of ß2-m (wild-type and 
variant) proteins with thrombin; in these experiments, digestion was initiated by addition 
of 20 L thrombin (0.05 mU/mL) to the protein solution (0.35 mg/mL) at an enzyme to 
substrate concentration ratio of 1:100. Aliquots were removed from the reaction at the 
following time points:  0, 0.08, 0.5, 1, and 3 hr.  All reaction samples from both the 
trypsin and thrombin experiments were frozen and stored at -4 C for analysis by SDS-
PAGE as described previously.  
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Wild-type and P32L samples at 0, 1, and 21 hr from limited proteolysis with 
thrombin were sent to University of Massachusetts Medical (Worcester, MA) for mass 
spectrometry analysis.  
Aggregation  
 Aggregation of wild-type and variant ß2-m proteins were evaluated using 
thioflavin T (ThT) fluorescence.  Solutions containing 0.4 mg/mL ß2-m in sample buffer 
with 10 µM ThT and 0.05% sodium azide were prepared.  A 96-well costar black clear 
bottom plate (Corning Inc., Corning, NY) was used in this study and each ß2-m protein 
was allotted 6 wells; 3 of the 6 wells for each protein contained 10 µL trypsin (0.05 
mg/mL) which was added initially.  Protein solutions (100 µL) were then appropriately 
loaded into all wells; in wells containing protease, the enzyme to substrate concentration 
ratio was 1:100.  The bottom reading plate was run on a fluorescence microplate reader 
(Molecular Devices, San Jose, CA) at 37 C for 1200 cycles over 100 hr.  The excitation 
and emission wavelengths were 450 nm and 482 nm, respectively; shaking for 280 sec 
was performed between each read.  An identical protocol was used to study the effect of 
thrombin; the enzyme to substrate concentration ratio for thrombin and ß2-m samples was 
1:100.  Samples were taken from wild-type and variant ß2-m protein wells and stored for 
electron microscopy.  
 Precipitants were scratched from the bottom of each well with a pipet tip before 
removal of the sample from each plate for transfer to an eppendorf tube.  Tubes 
containing the test solution were spun at 12,000 x g for 15 min to collect any precipitant 
materials.  From each tube, supernatant was removed, and pellets were resuspended with 
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20 L SDS loading buffer (2X) with 5% BME for analysis by SDS-PAGE as described 
previously.  
Electron Microscopy  
 Transmission electron microscopy was performed on ß2-m protein samples (wild-
type and variants) from the ThT aggregation studies detailed above.  The ultrastructural 
analysis was conducted in the Department of Physiology and Biophysics at Boston 
University School of Medicine under the direction of Dr. Esther Bullitt.  A 4 L drop 
containing ~ 0.1 mg/mL ß2-m was placed onto an EM grid and stained with 1% uranyl 
acetate.  Electron micrographs were collected at 56,000X-magnification using a CM12 
transmission electron microscope (Philips Electron Optics, the Netherlands) equipped 






Recombinantly-generated proteins serve as human ß2-m protein replicates 
Site directed mutagenesis of wild-type ß2-m gene facilitates expression of 
variant ß2-m proteins  
Appropriate nucleotide sequences for generating recombinant human P32L, 
D76N, and P32G ß2-m proteins were confirmed by DNA Sanger sequencing of the ß2-m 
mutant plasmids.  Figure 13 shows the DNA sequence results obtained on each ß2-m 
recombinantly-generated mutant; the codon containing the key mutation(s) in each 
mutant is highlighted.  For P32L, the abnormality involves a nucleotide sequence 
variation at the second base position in codon 32 of the ß2-m gene.  Specifically, the 
DNA alteration involves a C to T transition (CCG to CTG) resulting in proline to leucine 
substitution.  For D76N, the abnormality involves a nucleotide sequence variation at the 
first base position in codon 76 of the ß2-m gene.  Specifically, the DNA alteration 
involves a G to A transition (GAC to AAC) resulting in aspartic acid to asparagine 
replacement.  For P32G, the irregularity involves a dinucleotide sequence variation at the 
first and second base positions in codon 32 of the ß2-m gene.  Explicitly, the DNA 
alteration involves a C to G transition (CCG to GGG) at both base positions resulting in a 






Figure 13.  DNA sequences of recombinant wild-type and mutant ß2-m.  Mutations 
for each variant are boxed.  For P32L, CCG is mutated to CTG at nucleotide 95 (shown 
in red box); for D76N, GAC is mutated to AAC at nucleotide 226 (shown in green box); 
and for P32G, CCG is mutated to GGG at nucleotides 94 and 95 (shown in blue box).  
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Concentration of proteins were calculated from measurement of UV absorption at 
280 nm using the extinction coefficient of 20,065 M-1cm-1.  All spectra for each protein 
showed sharp and uniform peaks at A280 confirming purity. 
N-terminal MKH6 tag removal yields highly purified recombinant  proteins with 
biochemical features that are consistent with human ß2-m   
For N-terminal MKH6 tag removal from proteins, optimal digestion reaction time 
and temperature were determined initially.  Tags were enzymatically removed from the 
recombinant wild-type and variant proteins, P32L and D76N, using TAGZyme DAPase.  
Digestions were performed at both room temperature and 37 C for comparison; all 
reactions were assessed by SDS-PAGE using samples taken at 1 hr and 48 hr after 
addition of the enzyme.  The electrophoretic results from this comparative study, shown 
in Figure 14, demonstrate no marked temperature- or time-dependent differences among 
the samples.  All conditions were equally effective in removing the MKH6 tags from the 
wild-type and variant ß2-m proteins.  However, the staining intensities of the SDS-PAGE 
bands for proteins digested after 1 hr at room temperature were higher than those at the 
later time point (48 hr) and higher temperature (37 C).  Therefore, enzymatic digestion 
for 1 hr at room temperature was chosen as the optimal procedure and used for N-





Figure 14.  SDS-PAGE analysis of N-terminal MKH6 tag removal from 
recombinant ß2-m proteins for optimization study.  Wild-type, D76N and P32L ß2-m 
samples were digested with DAPase at room temperature or 37 C for 1 hr or 48 hr.  
SDS-PAGE was used to determine temperature- and time-dependent conditions that 
yielded the most effective results. 
 
Using the optimized reaction conditions, digestions were performed and removal 
of MKH6 tags from all wild-type and variant ß2-m proteins (D76N, P32L and P32G) was 
confirmed by SDS-PAGE (Figure 15).  Analyses of proteins from pre- and post-
treatment with DAPase at room temperature, (0 and 1 hr, respectively) showed an 
appropriately sized decrease in molecular weight (Mr) for all digested samples.  The gel 
bands at the 0 time points, representing the His-tagged proteins, exhibit a Mr of ~13 kD, 
while those post-digestion (1 hr) showed a Mr of ~12 kD.  These post-digestion results 
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are consistent with the known Mr of ß2-m (11.8 kD), thus indicating that the MKH6 tag 
had been successfully removed from the proteins. 
 
 
Figure 15.  SDS-PAGE confirmation of N-terminal MKH6 tag removal.  SDS-PAGE 
analysis of wild-type and variant (D76N, P32L, and P32G) ß2-m samples pre- and post-
digestion time of 1 hr with DAPase at room temperature. 
 
Wild-type and P32L ß2-m proteins were analyzed by mass spectrometry to assess 
purity.  Mass spectrometry showed that protein samples were pure and also confirmed 
that the N-terminal MKH6 tag was completely removed.  This is illustrated by the single 





Figure 16.  Mass spectrometry of wild-type and P32L proteins post-purification.  
Samples of both wild-type (A) and P32L (B) were analyzed by MS after purification and 
N-terminal MKH6 removal.  
 
Wild-type and variant recombinant ß2-m proteins share similar secondary 
structures differentially affected by the presence of N-terminal MKH6 tags  
 The secondary structures of recombinant wild-type, D76N, P32L and P32G ß2-m 
proteins, with and without N-terminal tags, were analyzed using CD spectroscopy and 
compared (Figure 17).  The spectra of all tagged recombinant ß2-m proteins in this study 
(Figure 17A) showed a high degree of structural similarity.  Moreover, all tagged 
recombinant ß2-m proteins exhibited spectra that were comparable to the matched 
counterparts without tags (Figure 17B).  Overall, the entire group of studied proteins, 
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with and without N-terminal MKH6 tags, showed a negative peak at ~218 nm indicating 
folded conformations comprised mainly of beta sheet secondary structure. 
 
 
Figure 17.  CD spectra of recombinant wild-type, D76N, P32L and P32G ß2-m 
proteins.  Far-UV CD spectra of wild-type (solid black line), D76N (solid green line), 
P32L (solid red line) and P32G (solid blue line) with N-terminal MKH6 tags at 25 C (A).  
Far-UV CD spectra of wild-type (dashed black line), D76N (dashed green line), P32L 
(dashed red line) and P32G (blue dashed line) at 25 C without the N-terminal MKH6 
tags (B).  The ß2-m protein concentration in all samples was 0.25 mg/mL. 
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 These far-UV CD data (wavelength range, 190-250 nm) were used to estimate the 
percentages of alpha helices and beta sheets present in the secondary structures of wild-
type, D76N, P32L and P32G ß2-m.  Results were obtained with the CDpro program and 
are shown in Table 7.  N-terminal MKH6 tagged-wild-type, -P32L and -P32G each 
contained ~67.2% beta sheet secondary structure, while MKH6 tagged-D76N showed 
slightly less (~63.7%).  MKH6 tagged-D76N had the highest percentage of unordered 
structure at ~35.2% followed by P32G, wild-type and P32L at ~30.6%, ~29.0% and 
~28.7%, respectively.  The lower beta sheet content and higher unordered structure 
indicated that MKH6 tagged-D76N was the least stable tagged protein. 
 Analysis of the CD data generated on the proteins without N-terminal MKH6 tags 
revealed slightly different secondary structure estimates compared to the tagged group.  
In the proteins with no tag, wild-type ß2-m had the highest percentage of beta sheet 
secondary structure at ~71% followed by P32L, D76N, and P32G with ~65.2%, ~64.6% 
and 62.9%, respectively.  Without tag, P32G had the highest amount of unordered 
secondary structure at ~34.1%, followed by P32L, D76N and wild-type with ~29.3%, 
~29.1% and ~26.1% respectively.  P32G had the lowest beta sheet content and highest 
unordered secondary structure.  Wild-type had the highest percentage of beta sheet and 
lowest percentage of unordered structure.  These secondary structure estimates suggest 
that wild-type and D76N are higher ordered when the N-terminal His tag is removed, i.e., 
the beta sheet content increased, and unordered structure decreased compared to the 
tagged proteins.  Conversely, with P32L and P32G, our data suggest that both variants 
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are less ordered when the N-terminal tag is removed; beta sheet content was decreased 
and unordered structure increased when compared to the tagged counterparts. 
 
Table 7.  Secondary structures of wild-type and variant ß2-m proteins with and 
without N-terminal MKH6 tag. 
 
 
Wild-type and P32L feature mainly ß-sheet secondary structure and differing 
thermal stabilities 
 The structure and stability of ß2-m recombinant proteins were studied by circular 
dichroism (CD) spectroscopy.  Initially, the secondary structure of wild-type ß2-m 
without N-terminal tag was analyzed.  Figure 18A shows the far-UV CD spectrum of the 
protein at 25 C (black open circles) with a negative peak at ~220 nm and positive peak 
at ~200 nm.  These data are characteristic of protein secondary structure that is organized 
primarily in a beta sheet conformation; in addition, the results confirm that the 
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recombinantly-generated wild-type ß2-m is properly folded, i.e., it displays the same 
structural arrangement as has been reported for the native human protein.  To assess 
protein stability, wild-type ß2-m was heated to 75 C (black diamonds with cross); this 
resulted in drastic structural changes to the protein including the loss of the positive peak 
at ~200 nm and appearance of a negative peak at 202 nm, characteristics indicating a 
predominately unfolded protein.  Cooling the protein back to 25 C (black filled 
triangles) did not yield data that were similar to the original spectrum of the protein at 25 
C.  Non-coincident curves for the protein pre- and post-heating suggested that wild-type 
ß2-m was thermally denatured upon heating to 75 C and that this unfolding process was 
largely irreversible.  
 The same analyses using far-UV CD spectroscopy was performed on 
recombinantly-generated P32L ß2-m in the absence of the N-terminal tag.  In Figure 
18B, the spectrum of the variant protein at 25 C (red open circles) shows a negative peak 
at ~218 nm, indicating high levels of beta sheet secondary structure and confirming a 
native folded state.  When P32L ß2-m was heated to 75 C (red diamonds with cross), 
major spectral changes were observed, including a negative dip at ~202 nm, indicating an 
unfolded protein and loss of secondary structure.  Upon return to 25 C (red filled 
triangles), the spectrum was similar to that obtained on the protein at 25 C prior to 
heating; these data suggest that once thermally unfolded, P32L ß2-m can partially refold 
with removal of heat.  Thus, unlike the wild-type protein, unfolding of the P32L variant is 
mostly reversible.  In Figure 18, the arrow at 205 nm indicates the wavelength used for 
assessing thermostabilities of the proteins in subsequent experiments.  This 205 nm value 
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was chosen to monitor the secondary structures of the ß2-m proteins since a large 














Figure 18.  CD spectroscopic comparison of wild-type and P32L ß2-m thermal 
unfolding and refolding.  Far-UV CD spectra of wild-type ß2-m (0.25 mg/mL) at 25 C 
(open circles) and of the same sample heated to 75 C (diamonds with cross) followed by 
cooling to 25 C (filled triangles) at a rate of 1 C per min (A).  Far-UV CD spectra of the 
P32L variant at 25 C (open circles) and of the same sample heated to 75 C (diamonds 
with cross) followed by cooling to 25 C (filled triangles) at a rate of 1 C per min (B).  
Monitoring of protein secondary structure during unfolding and refolding was performed 
at 205 nm. 
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 In a separate experiment, the thermal stability of ß2-m P32L was further examined 
by CD spectroscopy.  The P32L sample was heated and cooled as in the previous study 
but monitored at one wavelength (205 nm) to precisely determine the effect temperature 
on unfolding and refolding (Figure 19).  As the temperature increased, the fraction of 
unfolded to folded protein increased as expected.  A comparison of the spectra generated 
from the heating and cooling data showed a similar pattern in both processes; however, 
the two curves are not coincident indicating that unfolding-refolding of the protein was 
not completely reversable.  This finding was consistent with previous results.  The 
apparent melting temperature (Tm app), where 50% of the protein is folded and 50% is 
unfolded, was estimated to be ~58C for the heating curve of P32L.  Tm app was 
determined as the maximum point from the first derivative of the heating data.  These 






Figure 19.  CD analysis of P32L ß2-m thermal unfolding and refolding.  Far-UV CD 
spectra of (0.25 mg/mL) P32L ß2-m heated from 25 C to 75 C (top hatched line) and 
cooled from 75 C to 25 C (lower hatched line).  Heating and cooling of the sample 
were performed consistently at a rate of 1 C/min with monitoring at 205 nm.  The 
vertical arrow denotes the apparent melting temperature (Tm app), determined as the 







Stabilities of recombinant wild-type and variant ß2-m proteins vary and can be 
influenced by the presence of N-terminal MKH6 tags 
 Thermal denaturation demonstrates increased stability in wild-type, D76N and 
P32L ß2-m proteins with removal of His tags 
 The thermal stabilities of wild-type, D76N, P32L and P32G ß2-m proteins, with 
and without N-terminal MKH6 tags, were compared using CD spectroscopy (Figure 20).  
Spectra were taken at 205 nm while heating at a rate of 1C/min.  The Tm app was 
determined for each protein as the maximum value from the first derivative of each CD 
melting curve.  For tagged proteins, wild-type had the highest Tm app value at ~60C, 
followed by P32L and P32G both at ~55C, and finally D76N at ~50C (Figure 20A).  
This indicates that among the tagged group, wild-type ß2-m was the most thermally stable 
and D76N was the least with the lowest Tm app.  Removal of the N-terminal tag caused 
changes in the transition temperature for each protein except P32G.  Untagged wild-type 
ß2-m had the highest Tm app at ~64C, followed by P32L, P32G and D76N at ~58C, 
~55C, and ~52C, respectively (Figure 20B).  Overall, the removal of the N-terminal 
MKH6 tag increased the Tm app and therefore, the thermal stability for all proteins, except 




Figure 20.  Thermal stabilities of recombinant wild-type and variant ß2-m proteins, 
with and without N-terminal MKH6 tags, assessed by CD spectroscopy.  Tagged (A) 
and untagged (B) wild-type, D76N, P32L and P32G were analyzed by CD spectroscopy 
with monitoring at 205 nm during heating from 30 to 80 C at a rate of 1C/min.  The 
apparent transition temperature (Tm app) for each protein was determined as the maximum 
value of the first derivative from each CD melting curve.  The ß2-m protein concentration 
in all samples was 0.25 mg/mL. 
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 Chemical denaturation study results are consistent with thermal unfolding data 
In addition, the stabilities of wild-type, D76N, P32L and P32G ß2-m, with and 
without N-terminal MKH6 tags, were also assessed by chemical denaturation of the 
proteins (Figure 21) in a series of increasing guanidine hydrocholoride (HCl) 
concentrations (0 to 4 M).  Tryptophan fluorescence was measured at 355 nm and 335 nm 
for each sample and expressed as the ratio of the two values (I355/I335) to represent protein 
unfolding.  For tagged ß2-m proteins, wild-type was the most stable followed by P32L, 
P32G and D76N (Figure 21A).  While there was only slight variation in stability among 
the four ß2-m proteins, D76N appeared to be the least stable; an increase in fluorescence 
ratio (355/335 nm) as a function of increasing guanidine HCl concentration showed that 
D76N required the least chemical denaturant (~1.4 M) to be 50% unfolded.  Conversely, 
more variation was observed among the proteins in which the N-terminal MKH6 tags had 
been removed (Figure 21B).  D76N and P32G appeared to be the least stable with the 
lowest concertation of guanidine HCl (~1.6 M) needed to unfold 50% of the protein, 
followed by P32L and wild-type requiring ~2.0 M and ~2.4 M guanidine HCl, 
respectively.  Wild-type was the most stable of the four proteins needing the highest 
concentration of guanidine to trigger denaturation.  These chemical denaturation data 
were consistent with results from the previously described thermal unfolding experiments 
and suggested that removal of the N-terminal MKH6 tags from recombinant wild-type 





Figure 21.  Chemical denaturation of recombinant wild-type and variant ß2-m 
proteins.  Using guanidine hydrochloride, the chemical denaturation of wild-type, D78N, 
P32L and P32G ß2-m proteins with (A) and without (B) N-terminal MKH6 tags was 
assessed.  Each protein sample (0.03 mg/mL) was solubilized in a series of guanidine 
hydrochloride concentrations ranging from 0 to 4 M and allowed to stand at room 
temperature for 2 hours.  Data are presented as a ratio of fluorescence intensities at 355 
nm and at 335 nm. 
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Proteolysis of wild-type and variant ß2-m proteins have varying consequences which 
affect propensities to form amyloid fibrils   
The fragmentation of proteins is thought to play an important role in amyloid 
disease mechanisms 30; therefore, the ability of ß2-m proteins to form amyloid like 
structures pre- and post-proteolysis reactions was of interest.  Two proteases were chosen 
for study:  1) trypsin to provide ‘proof of concept’ results and 2) thrombin as a potential 
candidate mimicking the in vivo pathologic situation. 
ß2-m digestion reactions with trypsin are optimally performed in screw-topped 
glass vials 
 Optimization experiments were initially conducted to determine which conditions 
would be most effective for use in limited proteolysis of ß2-m proteins.  To assess 
appropriate reaction times and sample containers, N-terminal MKH6 tagged wild-type 
and P32L ß2-m were digested with trypsin for 5, 30, 60, and 120 min in three different 
containers at 37 C; at the end of each indicated time interval, a 20 L aliquot was 
removed from the reaction mixture and PMSF was added to stop the reaction.  The three 
types of sample containers under study were:  1) PCR tubes, 2) Eppendorf tubes, and 3) 
glass vials with screw tops.  Based on SDS-PAGE analysis (Figure 22), the glass vials 
with screw tops rendered the most optimal results, i.e., distinct bands for both undigested 
(~15 kD) and digested (~5 kD) proteins, especially in the wild-type samples.  In addition, 
the glass vials had less condensation than the plastic Eppendorf tubes which allowed the 
reaction concentrations to remain constant throughout the duration of the experiment.  
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Figure 22.  SDS-PAGE analysis of ß2-m limited proteolysis reaction conditions for 
optimization study.  Trypsin digestion of ß2-m samples (0.35 mg/mL) was performed to 
compare reaction times and the use of three different sample containers:  1) PCR tubes, 2) 
Eppendorf tubes, and 3) screw-topped glass vials.  SDS-PAGE was used to assess 
digestion reaction mixtures at 0, 5, 30, 60 and 120 min following addition of trypsin and 
halting of each reaction with PMSF (6 mM).  SDS-PAGE results for wild-type (A) and 
P32L (B) ß2-m digestion reaction are shown. 
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Trypsin digestions of wild-type and variant ß2-m proteins exhibit varying 
kinetics which are affected by the presence of the n-terminal MKH6 tag 
Wild-type, P32L, D76N and P32G ß2-m samples at (0.35 mg/mL) with N-
terminal MKH6 tags were subjected to limited tryptic digestion and analyzed by SDS-
PAGE (Figure 23).  The electrophoretic results suggested that all proteins were partially 
proteolyzed by 5 min following addition of the enzyme as demonstrated by the 
appearance of gel bands of lower Mr than the full-length ß2-m.  Compared to wild-type 
ß2-m (Figure 23A), the variant proteins appeared to be digested much more rapidly 
(Figure 23B-D) suggesting that the mutation causes greater instability.  Full-length wild-
type, represented by the gel band at ~12 kD, was observed throughout the entire reaction 
interval and marked reduction was seen only after 90-120 min, while variants were 
proteolyzed beginning at 5 min represented by the gel bands at ~5 kD.  To further 
demonstrate the differences, at the 30 min time point, it appeared that the amount of full-
length wild-type ß2-m was minimally reduced; conversely, very little full-length protein 





Figure 23.  SDS-PAGE analysis of recombinant N-terminally tagged ß2-m proteins 
digested with trypsin.  Limited proteolysis reaction mixtures were assessed at 0, 5, 10, 
30, 60, 90, 120, 240, and 360 min following addition of trypsin and halting of each 
reaction with PMSF (6 mM).  SDS-PAGE results for wild-type (A), P32L (B), D76N (C), 
and P32G (D) ß2-m proteins are shown.  The ß2-m concentration of all reaction mixtures 
was 0.35 mg/mL; substrate/enzyme ratio was 100:1 and digestions were performed at 
37C in sealed screw-topped glass vials.   
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The same limited tryptic digestion reaction and analysis by SDS-PAGE was 
performed on wild-type and variant proteins without N-terminal MKH6 tags for 
comparison to the tagged ß2-m proteolysis results (Figure 24).  The untagged wild-type 
protein showed little evidence of proteolysis; there was only slight diminution of the full-
length protein band at ~12 kD and no detectable discrete lower Mr weight gel bands, 
indicating that the removal of the His tag produced a more stabilized protein.  For D76N 
and P32L, digestion products were present at all time intervals measured from 5-120 min, 
similar to results obtained with the tagged counterparts.  However, the untagged full-
length proteins were only partially digested after 30-60 min and a small amount was still 
visible at 120 min.  The proteolysis of P32G showed digestion products (Mr < 11.6 kD) 
at ~30, 60 and 120 min and a small amount of full-length protein at 60 min; these results 
differ from those obtained on tagged P32G which yielded lower Mr reaction products at 5 
min and no undigested full-length protein after 30 min.  Similarly, to the N-terminally 
tagged proteins, the ß2-m variants with tags appeared to be digested more rapidly than the 





Figure 24.  SDS-PAGE analysis of recombinant ß2-m proteins without N-terminal 
MKH6 tags digested with trypsin.  Limited proteolysis reaction mixtures were assessed 
at 0, 5, 10, 30, 60 and 120 min following addition of trypsin and halting of each reaction 
with PMSF (6 mM).  SDS-PAGE results for wild-type (A), P32L (B), D76N (C) and 
P32G (D) are shown.  The ß2-m concentration of all reaction mixtures was 0.35 mg/mL; 
substrate/enzyme ratio was 100:1 and digestions were performed at 37C in sealed screw-
topped glass vials. 
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Thrombin proteolysis of wild-type or P32L ß2-m may require extended reaction times 
ß2-m proteins without N-terminal tags were subjected to limited thrombin 
digestion and reaction mixtures analyzed by SDS-PAGE (Figure 25).  Thrombin is a 
protease hypothesized to cleave the N-terminus of ß2-m, creating a truncated version of 
the protein that is known to lose stability and have amyloidogenic properties.  In our 
limited proteolysis studies with thrombin, we did not observe any digestion of wild-type, 
P32L or D76N ß2-m after a 3 hr digestion reaction with the enzyme (Figure 25A-C).  
From SDS-PAGE analysis, it appeared that thrombin had little to no effect on any of the 












Figure 25.  SDS-PAGE analysis of recombinant ß2-m proteins without N-terminal 
MKH6 tags digested with thrombin.  Limited proteolysis reaction mixtures were 
assessed at 0, 0.08, 0.5, 1 and 3 hr following addition of thrombin and halting of each 
reaction with PMSF (6 mM).  SDS-PAGE results for wild-type (A), P32L (B) and D76N 
(C) are shown.  The ß2-m concentration of all reaction mixtures was 0.35 mg/mL; 
substrate/enzyme ratio was 100:1 and digestions were performed at 37C in sealed screw-
topped glass vials 
 
Wild-type and P32L (no His tag) samples from limited proteolysis with thrombin 
were further analyzed by mass spectrometry (MS) to determine if thrombin cleaved either 
protein.  Samples were collected prior to and after addition of thrombin at 0, 1 and 21 hr. 
Based on the MS results (Figure 26A, B), neither wild-type nor P32L was cleaved by 
thrombin as indicated by the appearance of only one large peak in each spectrum at an Mr 
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of ~11.8 kD.  However, these data confirmed the purity of each protein sample and the 
complete removal of the His tag.  
 
 
Figure 26.  Mass spectrometry of wild-type and P32L proteins pre- and post-
thrombin digestion.  Digestion reaction samples of wild-type (A) and P32L (B) at 0, 1 





 Aggregation of wild-type and variant ß2-m treated with trypsin and thrombin is 
variable among the proteins and protease-dependent 
 To test whether fragments generated from limited proteolysis of wild-type and 
variant ß2-m proteins formed amyloid fibrils, a time course of aggregation monitoring by 
thioflavin T (ThT) measurements was performed.  ThT is a fluorescent dye whose 
emission increases when bound to an amyloid like structure.  The experiment was run in 
the absence of protease, trypsin or thrombin.  
Initially, the abilities of the untagged and full-length ß2-m proteins to form 
amyloid fibrils in the absence of protease was tested.  Wild-type, P32L, D76N and P32G 
solutions were incubated at 37 C with shaking over a time span of 40 hr and monitored 
with ThT (Figure 27).  Wild-type and variant ß2-m proteins did not show any increase in 
ThT fluorescence indicating that little aggregation or fibril formation had occurred with 





Figure 27.  ThT fluorescence of untagged wild-type and variant ß2-m proteins in the 
absence of protease.  Full-length wild-type, P32L, D76N and P32G ß2-m without N-
terminal MKH6 tags were individually solubilized in sample buffer at 0.4 mg/mL and 
incubated at 37 C with shaking for ~40 hr.  ThT fluorescence monitoring of the 
individual protein solutions was conducted continuously throughout the interval. 
 
ß2-m proteins mixed with trypsin to induce limited proteolysis reactions were 
monitored by ThT fluorescence emission to assess the formation of amyloid fibrils 
(Figure 28).  Wild-type, P32L, D76N or P32G ß2-m proteins without N-terminal MKH6 
tags were individually studied.  In the presence of trypsin, P32L showed an almost 
immediate ThT emission spike suggesting rapid aggregation of the sample.  Conversely, 
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little to no change in ThT emission was noted for wild-type, D76N and P32G ß2-m 
indicating minimal aggregation in the samples. 
 
 
Figure 28.  ThT fluorescence of untagged wild-type and variant ß2-m proteins 
digested with trypsin.  Full-length wild-type, P32L, D76N and P32G ß2-m without N-
terminal MKH6 tags were individually solubilized in sample buffer at 0.4 mg/mL, treated 
with trypsin at a substrate to enzyme ratio of 100:1, and incubated at 37 C with shaking 
for ~ 40 hr.  ThT fluorescence monitoring of the individual protein solutions was 




 Similarly, wild-type and variant ß2-m proteins were mixed with thrombin to 
induce limited proteolysis reactions and monitored by ThT fluorescence emission to 
assess aggregation and formation of amyloid fibrils (Figure 29).  In the presence of 
thrombin, wild-type, D76N and P32G each showed a rapid increase in ThT emission after 
variable lag times, suggesting that aggregation had occurred in the three samples.  
Conversely, P32L demonstrated no change in ThT emission indicating the absence of 












Figure 29.  ThT fluorescence of untagged wild-type and variant ß2-m proteins 
digested with thrombin.  Full-length wild-type, P32L, D76N and P32G ß2-m without N-
terminal MKH6 tags were individually solubilized in sample buffer at 0.4 mg/mL, treated 
with thrombin at a substrate to enzyme ratio of 100:1, and incubated at 37 C with 
shaking for ~40 hr.  ThT fluorescence monitoring of the individual protein solutions 
was conducted continuously throughout the interval. 
 
After ThT monitoring of ß2-m protein aggregation by trypsin or thrombin, 
precipitants were removed from the wells and analyzed by SDS-PAGE (Figure 30).  In 
the wild-type ß2-m sample treated with trypsin, only a few faint higher Mr (>75 kD) gel 
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band were observed by electrophoretic analysis; however, a gel band at ~10 kD and a 
series of higher Mr bands (>12 kD) were observed in the reaction mixture with thrombin 
(Figure 30A).  These results together with the ThT data indicated that there was 
minimally detectable aggregation of the wild-type protein with trypsin.  Conversely, ThT 
and electrophoretic data suggested that the thrombin-treated wild-type sample was altered 
by the enzyme in a way that caused aggregation and formation of a precipitant.  Similar 
to the wild-type protein, D76N ß2-m showed no indication of aggregation with trypsin but 
did yield complimentary ThT and electrophoretic data (gel band at band at ~10 kD and 
>12 kD) suggesting aggregation of the protein with thrombin (Figure 30A).   
The P32L ß2-m variant treated with trypsin showed complete disappearance of the 
full-length protein (Mr ~12 kD) and a single discrete band at 5 kD by SDS-PAGE; in the 
thrombin-treated sample, two distinct bands one at ~10 kD and ~5 kD and a series of 
higher Mr (>12 kD) gel bands were observed (Figure 30B).  This indicated that digestion 
of the protein occurred with both trypsin and thrombin, likely resulting in aggregation of 
the reaction products most especially as evidence in the thrombin-treated sample.  Results 
obtained from the trypsin and thrombin proteolysis of P32G ß2-m resembled data from 
the P32L experiments.  P32L treated with trypsin showed a single band at ~5 kD by SDS-
PAGE; however, treatment with thrombin yielded a band at ~10 kD and a series of higher 
Mr (>12 kD) gel bands.  Interestingly, unlike P32L, there was no evidence of a ~5 kD 
band in the P32G sample from the thrombin treatment experiment.  These data suggest 
that P32G is digested with treated with trypsin or thrombin and the formation of 




Figure 30.  SDS-PAGE analysis of ß2-m proteins after treatment with either trypsin 
or thrombin.  Precipitants of aggregated wild-type and D76N (A) of P32L and P32G (B) 
ß2-m proteins digested with either trypsin or thrombin were obtained from the wells of 
the plate used in the ThT fluorescence assay and analyzed by SDS-PAGE.   
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 Electron microscopy assessment of recombinant wild-type and variant (P32L, 
D76N and P32G) ß2-m protein precipitants from the aggregation experiment were 
obtained (Figure 31).  There was a distinct difference in protein samples obtained from 
the trypsin compared to thrombin proteolysis reactions.  Pre-fibril oligomeric assemblies 
(annular or donut-shaped structures) were observed in P32L variant samples from the 
trypsin digestion, but no similar structures were seen with the trypsin-treated wild-type, 
D76N or P32G samples.  Amorphous aggregates were noted in all thrombin-treated 
samples.  These data suggest that thrombin and trypsin have differing effects on wild-







Figure 31.  Electron microscopy of wild-type and mutant ß2-m protein precipitants 
formed from aggregation experiments.  Shown are wild-type, D76N, P32L and P32G 
ß2-m proteins following treatment with either trypsin or thrombin as indicated. White 
arrows in the expanded panel denote pre-fibril oligomeric structures observed in the P32L 










For our studies, we generated recombinant ß2-m proteins that contained an N-
terminal MKH6 tag which allows rapid and effective purification.  However, as the 
tagged proteins are not truly representative of the in vivo structures, we sought to track 
any contribution specific to the N-terminal adduct by using proteins with and without an 
N-terminal MKH6 tag in most of our experiments.  Little to no variation in results was 
noted with the presence of the N-terminal MKH6 tag in some of our experiments, e.g., 
chemical denaturation and limited proteolysis.  However, removal of the MKH6 tag 
seemed generally to slightly increase the stability of the ß2-m proteins.  This was seen 
when comparing the secondary structures of the tagged and untagged proteins.  The 
estimated secondary structure data suggested that wild-type and D76N were more 
ordered when the His tag was removed; the beta sheet content increased, and unordered 
structure decreased compared to the tagged proteins.  This stability trend was also 
apparent in the thermal denaturation experiments.  Overall, the removal of the N-terminal 
MKH6 tag increased the Tm app and therefore, the thermal stability for all proteins except 
the synthetic variant, P32G, which remained unchanged.  Moreover, limited proteolysis 
experiments with trypsin, showed that ß2-m variants with His tags appeared to be 
digested more rapidly than the untagged proteins suggesting an increased resistance to 
proteolysis, i.e., an increased protein stability. 
His tags, because of their small size, are not thought to significantly interfere with 
the structure and function of proteins.  Yet, there are an increasing number of reposts 
suggesting the opposite31.  One study showed that the presence of a His tag decreased 
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thermal stability in the majority of proteins that were investigated even though the 
differences in stability were not found to be substantial31.  These observations are in 
agreement with our data and the effects noted with and without the presence of the tag on 
the ß2-m proteins in the present study.  Although the reasons for His tag destabilization of 
a protein are not completely understood, we hypothesized that the adduct interferes with 
native state molecular interactions that normally occur at the N-terminus of ß2-m and this 
disruption results in a less stable protein.  
 Our thermal and chemical denaturation experiments showed that wild-type ß2-m 
and D76N exhibit the highest and lowest stabilities in the group of protein studied, 
respectively.  D76N demonstrated a high amount of unordered secondary structure, while 
wild-type featured a low level of unordered structure and high quantity of beta sheet 
secondary structure.  In addition, wild-type also had the highest thermal and chemical 
stability, whereas D76N had the lowest.  The P32L and P32G variants exhibited similar 
stabilities; our CD data showed that both proteins were less unstable than wild-type, but 
more stable than D76N.  Although P32L ß2-m was not the most unstable of the proteins 
we studied, it still was shown to have amyloidogenic properties.  This is evident from 
both the clinical and experimental data, including extensive amyloid deposition in the fat 
pad aspirate from the proband (II-3) as revealed by Congo red staining and our ThT 
fluorescence and electron microscopic data suggesting aggregation and formation of 
P32L pre-fibril oligomeric structures.  
 P32 is located in the B-C loop of the ß2-m protein (Figure 32) and is highly 
conserved in many organism32.  ß2-m contains five peptidyl-prolyl bonds including one at 
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P32 that can be in a trans or cis conformation.  In its native state, the His 31 – Pro 32 
peptidyl-prolyl bond is in the cis formation which is thermodynamically unfavorable.  
The switch to the trans conformation can initiate the formation of non-native intermediate 
species that are able to self-associate.  When P32 is in the thermodynamically favorable 
trans conformation, it has been shown to trigger amyloid formation24.  The P32L 
mutation encodes the P32L ß2-m variant with an amino acid replacement that disturbs the 
native confirmation and likely renders the protein amyloidogenic.  
 
 
Figure 32.  Ribbon diagram representation of ß2-m protein secondary structure.  
The alpha helix is highlighted in red, and the beta sheets are highlighted in purple.  D76 
and P32 resides are indicated in tan font. 
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In vitro studies of ß2-m synthetic variants with alternative amino acids occupying 
the 32nd residue have been performed; in addition to P32G detailed in the current study, 
P32A, and P32V have also been investigated29,33,34.  All P32 variants demonstrated 
structural properties that are characteristic of amyloid fibril-forming species of ß2-m 
protein24.  The amyloidogenic variant P32L, studied in the present work, also showed 
similar biophysical properties and resulted in lower chemical and thermal stability 
compared to the wild-type protein.  This is supported by Figure 33, which shows an in 
silico prediction of amyloid propensity.  P32L shows higher consensus in two areas, both 
of which are around residue 32, compared to the wild-type protein.  
 
Figure 33.  Prediction of amyloid propensity of ß2-m wild-type and variant proteins.  




 Proteolytic fragmentation of proteins can play an important role in the amyloid 
disease mechanism30.  When digested with trypsin, proteolytic fragments and aggregates 
of P32L were produced as demonstrated in our ThT fluorescence monitoring and 
electrophoretic analysis.  Ultrastructural evaluation of the digest products by electron 
microscopy showed the P32L samples appeared to form self-assembled, annular shapes 
possibly indicative of amyloidogenic pre-fibrillar or -oligemic structures.  This illustrates 
that P32L has the potential to form amyloid fibrils. 
 In summary, the results of experiments reported in this thesis suggest that the N-
terminal MKH6 tag decreases the thermal stability of wild-type and all variant ß2-m 
proteins.  Overall, wild-type ß2-m was the most thermal and chemically stable of the 
proteins and D76N ß2-m was the least stable.  The protein of interest, P32L ß2-m, was 
less stable than the wild-type protein, but more stable than the D76N variant; moreover, 
P32L and P32G exhibited similar stabilities.  Though it is likely that the peptidyl-prolyl 
bond at residue 32 could contribute to the amyloidogenic property of P32L, more studies 
are required to test this hypothesis; for example, assessment of P32L tertiary structure by 
near UV spectroscopy would expand the current understanding of the amyloid forming 
features of this ß2-m variant.  We suggest the mechanism of ß2-m amyloidosis caused by 
P32L to be a result of the variant P32L dissociation from MHCI where it travels through 
the blood stream and is deposited in tissues and organs, specifically cardiac tissue 




Figure 34.  Model of P32L ß2-m amyloidosis.  Schema showing the disease pathway 
leading from ß2-m as a component MHCI to ß2-m fibril deposition in tissues and organs.   
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